Insider Selling: Precigen (NASDAQ:PGEN) CEO Sells $519,930.00 in Stock

Posted by Geri Gentry on Jun 4th, 2026

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) CEO Helen Sabzevari sold 119,250 shares of Precigen stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $4.36, for a total transaction of $519,930.00. Following the sale, the chief executive officer owned 3,768,872 shares in the company, valued at approximately $16,432,281.92. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $3.81 on Thursday. Precigen, Inc. has a fifty-two week low of $1.30 and a fifty-two week high of $5.47. The firm’s 50-day simple moving average is $4.06 and its 200 day simple moving average is $4.09. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. The stock has a market cap of $1.36 billion, a P/E ratio of -3.23 and a beta of 1.06.

Precigen (NASDAQ:PGEN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The business had revenue of $23.25 million for the quarter, compared to analysts’ expectations of $20.81 million. Equities analysts expect that Precigen, Inc. will post -0.02 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, Citizens Jmp boosted their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Precigen currently has a consensus rating of “Hold” and an average price target of $12.50.

Read Our Latest Report on Precigen

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently bought and sold shares of PGEN. State Street Corp raised its holdings in Precigen by 141.1% during the 4th quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after buying an additional 6,335,033 shares during the period. SymBiosis Capital Partners LLC acquired a new stake in Precigen during the 4th quarter worth about $12,540,000. Bank of America Corp DE raised its holdings in Precigen by 201.1% during the 3rd quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after buying an additional 1,673,731 shares during the period. Goldman Sachs Group Inc. raised its holdings in Precigen by 196.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock worth $9,087,000 after buying an additional 1,440,446 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in Precigen during the 3rd quarter worth about $2,796,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

(Get Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.